ASCO 2023 | The optimal sequence of ADCs and other therapies in advanced and metastatic urothelial cancer

Shilpa Gupta, MD, from the Cleveland Clinic, discusses the optimal sequence of antibody-drug conjugates (ADCs) and other therapies in advanced and metastatic urothelial cancer. With the approval of sacituzumab govitecan in the US, it presents a reasonable option for patients who progress after front-line pembrolizumab therapy. Additionally, FGFR inhibitors can be considered for patients with FGFR3 alterations. However, the efficacy of platinum-based chemotherapy as a second-line therapy after pembrolizumab remains uncertain. While platinum-based chemotherapies have traditionally been a front-line therapy, further research is needed to understand their effectiveness after pembrolizumab. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.